Effectiveness of double bolus alteplase in the treatment of acute myocardial infarction.

[1]  F. Dunn,et al.  A pilot study of the efficacy and safety of bolus administration of alteplase in acute myocardial infarction. , 1991, British heart journal.

[2]  White Hd.  GISSI-2 and the heparin controversy. , 1990 .

[3]  A. Maseri,et al.  Effectiveness of multiple bolus administration of tissue-type plasminogen activator in acute myocardial infarction. , 1990, The American journal of cardiology.

[4]  G. Agnelli.  Rationale for bolus t-PA therapy to improve efficacy and safety. , 1990, Chest.

[5]  E. Braunwald.  Enhancing thrombolytic efficacy by means of "front-loaded" administration of tissue plasminogen activator. , 1989, Journal of the American College of Cardiology.

[6]  U. Tebbe,et al.  Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.

[7]  V. Fidler,et al.  IMPROVED PRIMARY RENAL ALLOGRAFT SURVIVAL ON CYCLOSPORIN LIMITED TO WOMEN WITH PREVIOUS PREGNANCIES , 1989, The Lancet.

[8]  E. Seifried,et al.  Pharmacokinetics and Haemostatic Status During Consecutive Infusions of Recom binant Tissue-Type Plasminogen Activator in Patients with Acute Myocardial Infarction , 1989, Thrombosis and Haemostasis.

[9]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[10]  S. Forman,et al.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.

[11]  P. Ludbrook,et al.  Sustained Fibrinolysis After Administration of t-PA Despite Its Short Half-Life in the Circulation , 1987, Thrombosis and Haemostasis.

[12]  I. Palacios,et al.  Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. , 1986, Circulation.

[13]  J. Hirsh,et al.  The thrombolytic and hemorrhagic effects of tissue type plasminogen activator: influence of dosage regimens in rabbits. , 1985, Thrombosis research.

[14]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[15]  Brain Wr,et al.  Mind and matter. , 1951 .